Genfit S.A.

GNFT | NASDAQ

Price Alert Chart Builder DCF Calculator

$8.95

+$0.35 (+4.07%)

At close: Mar 9, 2026, 9:30 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+4.07%

(1D)

Rating

Updated: Mar 10, 2026

27.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $445.68M

1D Range

8.85 9

52W Range

2.55 10

Valuation (TTM)

PE -10.52

PB 7.21

EV/EBITDA -17.61

Valuation (NTM)

Forward PE N/A

Forward PEG -38.19

Price Target $13

Cash Flow

FCF Yield -1.1%

SBC Adj. FCF Yield -1.2%

SBC Impact -5.4%

Margins

Gross Margin 99.5%

Operating Margin -67.3%

FCF Margin -10.8%

Growth (CAGR)

Revenue 3Y | 5Y 74.5% | 50.0%

Dil EPS 3Y | 5Y 18.0% | 29.6%

FCF 3Y | 5Y 83.2% | 18.5%

Returns

ROA 1.0%

ROE 2.2%

ROIC 2.0%

Financial Health

Net Debt

€26.75M ($31.53M)

Current Ratio 1.23

Interest Coverage 0.69

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is...

Sector Healthcare

Industry Biotechnology

Employees 180

IPO Date Mar 26, 2019

Website www.genfit.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$13

Upside

+45.25%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞